Role of Nuclear Tyrosine Rak in Breast Cancer
Role of Nuclear Tyrosine Rak in Breast Cancer
批准号:
6358705
负责人:
FUNDA MERIC-BERNSTAM
金额:
$13.61万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-03 至 2006-07-31
关键词:
MCF7 cell apoptosis athymic mouse breast neoplasms cell cycle epidermal growth factor gene deletion mutation gene therapy growth factor receptors immunocytochemistry immunoprecipitation metastasis neoplasm /cancer therapy nonhuman therapy evaluation protein tyrosine kinase transfection /expression vector tumor necrosis factor alpha western blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tyrosine kinases are regulatory proteins
that play a central role in cell growth and differentiation. In preliminary
work, the expression of tyrosine kinases in breast cancer cell lines was
compared to normal-like breast cells using a tyrosine kinase differential
display assay. The nuclear tyrosine kinase Rak was downregulated or not
expressed in several breast cancer cell lines. Furthermore, the adenovirus
early gene E1A, which is known to inhibit the growth of breast cancer cell
lines, upregulated Rak expression. Enhanced expression of Rak in breast
cancer cells had a growth suppressing activity as measured by a decrease in
colony formation efficiency. Surprisingly, little is known about the role of
Rak in cells and its mechanism of action. This proposal will test the
hypothesis that Rak inhibits tumor cell growth, and that loss of expression of
Rak plays a role in breast cancer. First, the effect of Rak expression on
tumor cell growth will be assessed in vitro by cell counts, the colony
formation assay and the soft agar assay, and tested in vivo. Second, the
effect of Rak on the sensitivity of breast cancer cells to apoptosis and on
the cell cycle will be studied. The contribution of critical domains of Rak
to its function will be studied by deletion and mutation analysis. Third,
expression of Rak in breast cancers of various grades and metastatic
potentials will be determined by immunohistochemical analysis. These studies
will delineate the role of Rak in cell growth and its mechanism of action.
From a scientific standpoint, determining Rak's mechanism of action will
significantly enhance our understanding of how cell growth is regulated. From
a clinical standpoint, Rak may be a useful prognostic marker, and a gene
therapy agent. Furthermore, identifying Rak's role in tumor growth will allow
us to better tailor the specificity of tyrosine kinase inhibitors used in
clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
-
批准号:10652630
-
项目类别:
-
资助金额:$56.79万
-
财政年份:2022
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Research Project 3: Optimizing DNA damage repair-targeted combination therapy
-
批准号:10242642
-
项目类别:
-
资助金额:$21.81万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Evaluating drug combinations, efficacy and adaptive feedback in KRAS inhibition
-
批准号:10200357
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:9985264
-
项目类别:
-
资助金额:$144.75万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:10681971
-
项目类别:
-
资助金额:$55.76万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Research Project 3: Optimizing DNA damage repair-targeted combination therapy
-
批准号:10681972
-
项目类别:
-
资助金额:$10.77万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
University of Texas PDX Development and Trial Center
-
批准号:10242641
-
项目类别:
-
资助金额:$125.97万
-
财政年份:2017
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:6856714
-
项目类别:
-
资助金额:$24.6万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7339039
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7174303
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7540995
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Targeting mTOR for Cancer Therapy
-
批准号:7004523
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2005
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6844312
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:7011198
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6522694
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6712744
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
Role of Nuclear Tyrosine Rak in Breast Cancer
-
批准号:6630441
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2001
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
15 Developmental Therapeutics
-
批准号:10655559
-
项目类别:
-
资助金额:$1.87万
-
财政年份:1996
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:2196351
-
项目类别:
-
资助金额:$3.02万
-
财政年份:1995
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:2196350
-
项目类别:
-
资助金额:$2.89万
-
财政年份:1994
-
负责人:FUNDA MERIC-BERNSTAM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: